Skip to content

Boric Acid Versus 10% Povidone Iodine Solution in Treatment of Otomycosis

Boric Acid Versus 10% Povidone Iodine Solution in Treatment of Otomycosis: a Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07295210
Enrollment
60
Registered
2025-12-19
Start date
2024-12-01
Completion date
2025-12-01
Last updated
2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otomycosis

Brief summary

This study compares two topical agents for the treatment of fungal infection of the external auditory canal: boric acid and a 10% povidone-iodine solution

Interventions

Boric acid is topically applied to the external auditory canal for treatment of otomycosis

DRUGPovidone iodine 10%

10% povidone iodine solution is topically applied to the external auditory canal for the treatment of otomycosis

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* all consecutive patients with otomycosis, recruited from the outpatient clinic during the study duration

Exclusion criteria

* tympanic membrane perforation * previous ear surgery * significant medical co-morbidities such as poorly controlled diabetes or immunocompromised patients * patient refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
objective clinical responseDays 7, 14, and 28 after treatmentclinical response is assessed by ear examination by presence or absence of fungal hyphae inside the external auditory canal
Microbiological responseday 28 after treatmentMicrobiological response is evaluated by obtaining cultures from the external auditory canal searching for fungal growth

Secondary

MeasureTime frameDescription
subjective pain responsedays 7, 14, and 28 after treatmentpain is evaluated on a visual analogue scale from 0 to 10
subjective itching responsedays 7, 14, and 28 after treatmentitching is evaluated on a visual analogue scale from 0 to 10

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026